{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T12:45:01Z","timestamp":1793191501235,"version":"4.5.0"},"reference-count":113,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2020,9,5]],"date-time":"2020-09-05T00:00:00Z","timestamp":1599264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,9,5]],"date-time":"2020-09-05T00:00:00Z","timestamp":1599264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s40261-020-00953-z","type":"journal-article","created":{"date-parts":[[2020,9,5]],"date-time":"2020-09-05T11:02:46Z","timestamp":1599303766000},"page":"947-960","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Community-Acquired Bacterial Pneumonia\u2014Changing Epidemiology, Resistance Patterns, and Newer Antibiotics: Spotlight on Delafloxacin"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8374-9417","authenticated-orcid":false,"given":"Roopali","family":"Sharma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian E.","family":"Sandrock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joni","family":"Meehan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolette","family":"Theriault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,5]]},"reference":[{"issue":"6","key":"953_CR1","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1093\/jac\/dkx543","volume":"73","author":"BT Mogle","year":"2018","unstructured":"Mogle BT, Steele JM, Thomas SJ, Bohan KH, Kufel WD. Clinical review of delafloxacin: a novel anionic fluoroquinolone. J Antimicrob Chemother. 2018;73(6):1439\u201351.","journal-title":"J Antimicrob Chemother"},{"key":"953_CR2","volume-title":"Baxdela\u00ae (delafloxacin) product package insert","author":"Melinta Therapeutics Inc","year":"2017","unstructured":"Melinta Therapeutics Inc. Baxdela\u00ae (delafloxacin) product package insert. Lincolnshire: Melinta Therapeutics Inc; 2017."},{"issue":"7","key":"953_CR3","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.2217\/fmb.15.39","volume":"10","author":"F Van Bambeke","year":"2015","unstructured":"Van Bambeke F. Delafloxacin, a non-zwitterionic fluoroquinolone in phase III of clinical development: evaluation of its pharmacology, pharmacokinetics, pharmacodynamics and clinical efficacy. Future Microbiol. 2015;10(7):1111\u201323.","journal-title":"Future Microbiol"},{"key":"953_CR4","unstructured":"Melinta Therapeutics Inc. BAXDELA\u00ae package insert Lincolnshire, Illinois; 2019. Available from:\u00a0https:\/\/baxdela.com\/docs\/baxdela-prescribing-information.pdf. Accessed 12 Nov 2019."},{"key":"953_CR5","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ijid.2014.10.009","volume":"30","author":"W O\u2019Riordan","year":"2015","unstructured":"O\u2019Riordan W, Mehra P, Manos P, Kingsley J, Lawrence L, Cammarata S. A randomized phase 2 study comparing two doses of delafloxacin with tigecycline in adults with complicated skin and skin-structure infections. Int J Infect Dis. 2015;30:67\u201373.","journal-title":"Int J Infect Dis"},{"issue":"10","key":"953_CR6","doi-asserted-by":"crossref","first-page":"ofy220","DOI":"10.1093\/ofid\/ofy220","volume":"5","author":"T Lodise","year":"2018","unstructured":"Lodise T, Corey R, Hooper D, Cammarata S. Safety of delafloxacin: focus on adverse events of special interest. Open Forum Infect Dis. 2018;5(10):ofy220.","journal-title":"Open Forum Infect Dis"},{"issue":"7","key":"953_CR7","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1164\/rccm.201908-1581ST","volume":"200","author":"JP Metlay","year":"2019","unstructured":"Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019;200(7):e45\u201367.","journal-title":"Am J Respir Crit Care Med"},{"key":"953_CR8","unstructured":"File TM. Treatment of community-acquired pneumonia in adults who require hospitalization. UpToDate [Internet]. 2019.\u00a0https:\/\/www.uptodate.com\/contents\/treatment-of-community-acquired-pneumonia-in-adults-who-require-hospitalization."},{"issue":"Suppl 2","key":"953_CR9","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1086\/511159","volume":"44","author":"LA Mandell","year":"2007","unstructured":"Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America\/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(Suppl 2):S27\u201372.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"953_CR10","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1056\/NEJMoa1500245","volume":"373","author":"S Jain","year":"2015","unstructured":"Jain S, Self WH, Wunderink RG, Fakhran S, Balk R, Bramley AM, et al. Community-acquired pneumonia requiring hospitalization among U.S. adults. N Engl J Med. 2015;373(5):415\u201327.","journal-title":"N Engl J Med"},{"issue":"2","key":"953_CR11","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3810\/pgm.2010.03.2130","volume":"122","author":"TM File Jr","year":"2010","unstructured":"File TM Jr, Marrie TJ. Burden of community-acquired pneumonia in North American adults. Postgrad Med. 2010;122(2):130\u201341.","journal-title":"Postgrad Med"},{"issue":"2","key":"953_CR12","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1056\/NEJMoa1209165","volume":"369","author":"MR Griffin","year":"2013","unstructured":"Griffin MR, Zhu Y, Moore MR, Whitney CG, Grijalva CG. U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination. N Engl J Med. 2013;369(2):155\u201363.","journal-title":"N Engl J Med"},{"issue":"28","key":"953_CR13","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1016\/j.vaccine.2015.05.001","volume":"33","author":"MH Rozenbaum","year":"2015","unstructured":"Rozenbaum MH, Mangen MJ, Huijts SM, van der Werf TS, Postma MJ. Incidence, direct costs and duration of hospitalization of patients hospitalized with community acquired pneumonia: a nationwide retrospective claims database analysis. Vaccine. 2015;33(28):3193\u20139.","journal-title":"Vaccine"},{"issue":"6","key":"953_CR14","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1055\/s-0036-1592075","volume":"37","author":"JH Song","year":"2016","unstructured":"Song JH, Huh K, Chung DR. Community-acquired pneumonia in the Asia-Pacific region. Semin Respir Crit Care Med. 2016;37(6):839\u201354.","journal-title":"Semin Respir Crit Care Med"},{"issue":"1","key":"953_CR15","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/thx.2009.129502","volume":"67","author":"T Welte","year":"2012","unstructured":"Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax. 2012;67(1):71\u20139.","journal-title":"Thorax"},{"issue":"9","key":"953_CR16","doi-asserted-by":"crossref","first-page":"e673","DOI":"10.1016\/j.ijid.2013.02.006","volume":"17","author":"AR Buzzo","year":"2013","unstructured":"Buzzo AR, Roberts C, Mollinedo LG, Quevedo JM, Casas GL, Soldevilla JM. Morbidity and mortality of pneumonia in adults in six Latin American countries. Int J Infect Dis. 2013;17(9):e673\u20137.","journal-title":"Int J Infect Dis"},{"key":"953_CR17","unstructured":"World Health Organisation. The top 10 causes of death 2018. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/the-top-10-causes-of-death."},{"issue":"Suppl 3","key":"953_CR18","first-page":"iii1","volume":"64","author":"WS Lim","year":"2009","unstructured":"Lim WS, Baudouin SV, George RC, Hill AT, Jamieson C, Le Jeune I, et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax. 2009;64(Suppl 3):iii1\u201355.","journal-title":"Thorax"},{"issue":"Suppl 6","key":"953_CR19","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1111\/j.1469-0691.2011.03672.x","volume":"17","author":"M Woodhead","year":"2011","unstructured":"Woodhead M, Blasi F, Ewig S, Garau J, Huchon G, Ieven M, et al. Guidelines for the management of adult lower respiratory tract infections\u2014full version. Clin Microbiol Infect. 2011;17(Suppl 6):E1\u201359.","journal-title":"Clin Microbiol Infect"},{"issue":"17","key":"953_CR20","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1056\/NEJMra1312885","volume":"371","author":"DM Musher","year":"2014","unstructured":"Musher DM, Thorner AR. Community-acquired pneumonia. N Engl J Med. 2014;371(17):1619\u201328.","journal-title":"N Engl J Med"},{"issue":"11","key":"953_CR21","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1093\/cid\/cix647","volume":"65","author":"JA Ramirez","year":"2017","unstructured":"Ramirez JA, Wiemken TL, Peyrani P, Arnold FW, Kelley R, Mattingly WA, et al. Adults hospitalized with pneumonia in the United States: incidence, epidemiology, and mortality. Clin Infect Dis. 2017;65(11):1806\u201312.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"953_CR22","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1136\/thx.2010.143982","volume":"66","author":"C Cilloniz","year":"2011","unstructured":"Cilloniz C, Ewig S, Polverino E, Marcos MA, Esquinas C, Gabarrus A, et al. Microbial aetiology of community-acquired pneumonia and its relation to severity. Thorax. 2011;66(4):340\u20136.","journal-title":"Thorax"},{"issue":"3","key":"953_CR23","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1378\/chest.13-0062","volume":"144","author":"C Cilloniz","year":"2013","unstructured":"Cilloniz C, Polverino E, Ewig S, Aliberti S, Gabarrus A, Menendez R, et al. Impact of age and comorbidity on cause and outcome in community-acquired pneumonia. Chest. 2013;144(3):999\u20131007.","journal-title":"Chest"},{"issue":"3","key":"953_CR24","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","volume":"18","author":"AP Magiorakos","year":"2012","unstructured":"Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268\u201381.","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"953_CR25","doi-asserted-by":"crossref","first-page":"7","DOI":"10.5582\/bst.2016.01021","volume":"10","author":"Y Yu","year":"2016","unstructured":"Yu Y, Fei A. Atypical pathogen infection in community-acquired pneumonia. Biosci Trends. 2016;10(1):7\u201313.","journal-title":"Biosci Trends"},{"key":"953_CR26","first-page":"59","volume":"7","author":"C Tong","year":"2014","unstructured":"Tong C, Chen H. Research development on the diagnosis of atypical pathogens in community-acquired pneumonia. Chin J Lung Dis (Electron Ed). 2014;7:59\u201362.","journal-title":"Chin J Lung Dis (Electron Ed)"},{"issue":"10","key":"953_CR27","doi-asserted-by":"crossref","first-page":"e852","DOI":"10.1016\/j.ijid.2010.02.2262","volume":"14","author":"RE Isturiz","year":"2010","unstructured":"Isturiz RE, Luna CM, Ramirez J. Clinical and economic burden of pneumonia among adults in Latin America. Int J Infect Dis. 2010;14(10):e852\u20136.","journal-title":"Int J Infect Dis"},{"issue":"9998","key":"953_CR28","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/S0140-6736(15)60733-4","volume":"386","author":"E Prina","year":"2015","unstructured":"Prina E, Ranzani OT, Torres A. Community-acquired pneumonia. Lancet. 2015;386(9998):1097\u2013108.","journal-title":"Lancet"},{"issue":"140","key":"953_CR29","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1183\/16000617.0076-2015","volume":"25","author":"M Burk","year":"2016","unstructured":"Burk M, El-Kersh K, Saad M, Wiemken T, Ramirez J, Cavallazzi R. Viral infection in community-acquired pneumonia: a systematic review and meta-analysis. Eur Respir Rev. 2016;25(140):178\u201388.","journal-title":"Eur Respir Rev"},{"key":"953_CR30","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12879-015-0803-5","volume":"15","author":"JC Holter","year":"2015","unstructured":"Holter JC, Muller F, Bjorang O, Samdal HH, Marthinsen JB, Jenum PA, et al. Etiology of community-acquired pneumonia and diagnostic yields of microbiological methods: a 3-year prospective study in Norway. BMC Infect Dis. 2015;15:64.","journal-title":"BMC Infect Dis"},{"issue":"1","key":"953_CR31","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s12890-019-0944-1","volume":"19","author":"P Wongsurakiat","year":"2019","unstructured":"Wongsurakiat P, Chitwarakorn N. Severe community-acquired pneumonia in general medical wards: outcomes and impact of initial antibiotic selection. BMC Pulm Med. 2019;19(1):179.","journal-title":"BMC Pulm Med"},{"issue":"1","key":"953_CR32","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13054-019-2371-3","volume":"23","author":"C Cilloniz","year":"2019","unstructured":"Cilloniz C, Dominedo C, Torres A. Multidrug resistant gram-negative bacteria in community-acquired pneumonia. Crit Care. 2019;23(1):79.","journal-title":"Crit Care"},{"issue":"6","key":"953_CR33","doi-asserted-by":"crossref","first-page":"e619","DOI":"10.1016\/S2214-109X(18)30186-4","volume":"6","author":"A Versporten","year":"2018","unstructured":"Versporten A, Zarb P, Caniaux I, Gros MF, Drapier N, Miller M, et al. Antimicrobial consumption and resistance in adult hospital inpatients in 53 countries: results of an internet-based global point prevalence survey. Lancet Glob Health. 2018;6(6):e619\u201329.","journal-title":"Lancet Glob Health"},{"issue":"2","key":"953_CR34","first-page":"1","volume":"64","author":"J Xu","year":"2016","unstructured":"Xu J, Murphy SL, Kochanek KD, Bastian BA. Deaths: final data for 2013. Natl Vital Stat Rep. 2016;64(2):1\u2013119.","journal-title":"Natl Vital Stat Rep"},{"key":"953_CR35","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ijid.2016.05.021","volume":"49","author":"S Azmi","year":"2016","unstructured":"Azmi S, Aljunid SM, Maimaiti N, Ali AA, Muhammad Nur A, De Rosas-Valera M, et al. Assessing the burden of pneumonia using administrative data from Malaysia, Indonesia, and the Philippines. Int J Infect Dis. 2016;49:87\u201393.","journal-title":"Int J Infect Dis"},{"issue":"2","key":"953_CR36","doi-asserted-by":"crossref","first-page":"54","DOI":"10.4103\/0970-2113.63606","volume":"27","author":"BA Shah","year":"2010","unstructured":"Shah BA, Singh G, Naik MA, Dhobi GN. Bacteriological and clinical profile of community acquired pneumonia in hospitalized patients. Lung India. 2010;27(2):54\u20137.","journal-title":"Lung India"},{"key":"953_CR37","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1186\/1471-2334-13-296","volume":"13","author":"K Takahashi","year":"2013","unstructured":"Takahashi K, Suzuki M, le Minh N, Anh NH, Huong LT, Son TV, et al. The incidence and aetiology of hospitalised community-acquired pneumonia among Vietnamese adults: a prospective surveillance in central Vietnam. BMC Infect Dis. 2013;13:296.","journal-title":"BMC Infect Dis"},{"issue":"1","key":"953_CR38","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/apt.13652","volume":"44","author":"F Zingone","year":"2016","unstructured":"Zingone F, Abdul Sultan A, Crooks CJ, Tata LJ, Ciacci C, West J. The risk of community-acquired pneumonia among 9803 patients with coeliac disease compared to the general population: a cohort study. Aliment Pharmacol Ther. 2016;44(1):57\u201367.","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"953_CR39","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1136\/thoraxjnl-2015-207688","volume":"71","author":"TP Quan","year":"2016","unstructured":"Quan TP, Fawcett NJ, Wrightson JM, Finney J, Wyllie D, Jeffery K, et al. Increasing burden of community-acquired pneumonia leading to hospitalisation, 1998\u20132014. Thorax. 2016;71(6):535\u201342.","journal-title":"Thorax"},{"issue":"2","key":"953_CR40","doi-asserted-by":"crossref","first-page":"e0117716","DOI":"10.1371\/journal.pone.0117716","volume":"10","author":"C Cohen","year":"2015","unstructured":"Cohen C, Walaza S, Moyes J, Groome M, Tempia S, Pretorius M, et al. Epidemiology of severe acute respiratory illness (SARI) among adults and children aged\u2009\u2265\u20095\u00a0years in a high HIV-prevalence setting, 2009\u20132012. PLoS ONE. 2015;10(2):e0117716.","journal-title":"PLoS ONE"},{"issue":"Suppl 2","key":"953_CR41","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.4103\/0970-2113.99248","volume":"29","author":"D Gupta","year":"2012","unstructured":"Gupta D, Agarwal R, Aggarwal AN, Singh N, Mishra N, Khilnani GC, et al. Guidelines for diagnosis and management of community- and hospital-acquired pneumonia in adults: joint ICS\/NCCP(I) recommendations. Lung India. 2012;29(Suppl 2):S27\u201362.","journal-title":"Lung India"},{"issue":"11","key":"953_CR42","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1136\/thoraxjnl-2013-204282","volume":"68","author":"A Torres","year":"2013","unstructured":"Torres A, Peetermans WE, Viegi G, Blasi F. Risk factors for community-acquired pneumonia in adults in Europe: a literature review. Thorax. 2013;68(11):1057\u201365.","journal-title":"Thorax"},{"issue":"6","key":"953_CR43","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.21037\/jtd.2017.05.31","volume":"9","author":"TH Boyles","year":"2017","unstructured":"Boyles TH, Brink A, Calligaro GL, Cohen C, Dheda K, Maartens G, et al. South African guideline for the management of community-acquired pneumonia in adults. J Thorac Dis. 2017;9(6):1469\u2013502.","journal-title":"J Thorac Dis"},{"issue":"5","key":"953_CR44","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1164\/rccm.201501-0140OC","volume":"192","author":"DT Eurich","year":"2015","unstructured":"Eurich DT, Marrie TJ, Minhas-Sandhu JK, Majumdar SR. Ten-year mortality after community-acquired pneumonia. A prospective cohort. Am J Respir Crit Care Med. 2015;192(5):597\u2013604.","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"953_CR45","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.chest.2017.09.041","volume":"153","author":"BH Hayes","year":"2018","unstructured":"Hayes BH, Haberling DL, Kennedy JL, Varma JK, Fry AM, Vora NM. Burden of pneumonia-associated hospitalizations: United States, 2001\u20132014. Chest. 2018;153(2):427\u201337.","journal-title":"Chest"},{"key":"953_CR46","volume-title":"A Profile of Older Americans: 2017","author":"Administration on Community Living","year":"2018","unstructured":"Administration on Community Living. A Profile of Older Americans: 2017. Washington, DC: Administration for Community Living, Administration on Aging (AoA), U.S. Department of Health and Human Services; 2018."},{"key":"953_CR47","unstructured":"United Nations Department of Economic and Social Affairs. World population prospects: the 2017 revision, key findings and advance tables. Working Paper No. ESA\/P\/WP\/248. Population Division; 2017. Contract No.: Paper No. ESA\/P\/WP\/248."},{"key":"953_CR48","first-page":"37","volume":"53","author":"CC Tan","year":"2006","unstructured":"Tan CC, Ong-Mateo M. Management of community-acquired pneumonia in a university hospital: adherence to recommended practice guidelines. Santo Tomas J Med. 2006;53:37\u201344.","journal-title":"Santo Tomas J Med"},{"issue":"2","key":"953_CR49","first-page":"37","volume":"53","author":"CC Tan","year":"2006","unstructured":"Tan CC, Ong-Mateo M. Management of community-acquired pneumonia in a university hospital: adherence to recommended practice guidelines. Santo Tomas J Med. 2006;53(2):37\u201344.","journal-title":"Santo Tomas J Med"},{"issue":"4","key":"953_CR50","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.ejim.2013.12.001","volume":"25","author":"P Faverio","year":"2014","unstructured":"Faverio P, Aliberti S, Bellelli G, Suigo G, Lonni S, Pesci A, et al. The management of community-acquired pneumonia in the elderly. Eur J Intern Med. 2014;25(4):312\u20139.","journal-title":"Eur J Intern Med"},{"issue":"3","key":"953_CR51","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1159\/000479089","volume":"94","author":"J Almirall","year":"2017","unstructured":"Almirall J, Serra-Prat M, Bolibar I, Balasso V. Risk factors for community-acquired pneumonia in adults: a systematic review of observational studies. Respiration. 2017;94(3):299\u2013311.","journal-title":"Respiration"},{"issue":"7","key":"953_CR52","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1086\/428125","volume":"40","author":"CM Faulkner","year":"2005","unstructured":"Faulkner CM, Cox HL, Williamson JC. Unique aspects of antimicrobial use in older adults. Clin Infect Dis. 2005;40(7):997\u20131004.","journal-title":"Clin Infect Dis"},{"issue":"1-Supplement 1","key":"953_CR53","first-page":"S1","volume":"12","author":"K LaPensee","year":"2019","unstructured":"LaPensee K, Mistry R, Lodise T. Budget impact of omadacycline for the treatment of patients with community-acquired bacterial pneumonia in the United States from the hospital perspective. Am Health Drug Benefits. 2019;12(1-Supplement 1):S1\u201312.","journal-title":"Am Health Drug Benefits"},{"issue":"4","key":"953_CR54","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1080\/14728214.2019.1685494","volume":"24","author":"A Liapikou","year":"2019","unstructured":"Liapikou A, Cilloniz C, Palomeque A, Torres T. Emerging antibiotics for community-acquired pneumonia. Expert Opin Emerg Drugs. 2019;24(4):221\u201331.","journal-title":"Expert Opin Emerg Drugs"},{"key":"953_CR55","doi-asserted-by":"publisher","unstructured":"Moberley S, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev. 2013;(1):CD000422. https:\/\/doi.org\/10.1002\/14651858.CD000422.pub3.","DOI":"10.1002\/14651858.CD000422.pub3"},{"issue":"2","key":"953_CR56","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1086\/648678","volume":"50","author":"N Johansson","year":"2010","unstructured":"Johansson N, Kalin M, Tiveljung-Lindell A, Giske CG, Hedlund J. Etiology of community-acquired pneumonia: increased microbiological yield with new diagnostic methods. Clin Infect Dis. 2010;50(2):202\u20139.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"953_CR57","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s10096-012-1778-4","volume":"32","author":"MH Rozenbaum","year":"2013","unstructured":"Rozenbaum MH, Pechlivanoglou P, van der Werf TS, Lo-Ten-Foe JR, Postma MJ, Hak E. The role of Streptococcus pneumoniae in community-acquired pneumonia among adults in Europe: a meta-analysis. Eur J Clin Microbiol Infect Dis. 2013;32(3):305\u201316.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"5","key":"953_CR58","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1183\/09031936.00137412","volume":"42","author":"SM Huijts","year":"2013","unstructured":"Huijts SM, Pride MW, Vos JM, Jansen KU, Webber C, Gruber W, et al. Diagnostic accuracy of a serotype-specific antigen test in community-acquired pneumonia. Eur Respir J. 2013;42(5):1283\u201390.","journal-title":"Eur Respir J"},{"key":"953_CR59","unstructured":"Ramirez J. Overview of community-acquired pneumonia in adults. UpToDate [Internet]. 2019. https:\/\/www.uptodate.com\/contents\/overview-of-community-acquired-pneumonia-in-adults\/print."},{"issue":"2","key":"953_CR60","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3947\/ic.2018.50.2.160","volume":"50","author":"MS Lee","year":"2018","unstructured":"Lee MS, Oh JY, Kang CI, Kim ES, Park S, Rhee CK, et al. Guideline for antibiotic use in adults with community-acquired pneumonia. Infect Chemother. 2018;50(2):160\u201398.","journal-title":"Infect Chemother"},{"issue":"1","key":"953_CR61","first-page":"11","volume":"11","author":"T Nagesh Kumar","year":"2017","unstructured":"Nagesh Kumar T, Rafiudeen R, Rashmi K. A study of clinical and etiological profile of community-acquired pneumonia with special reference to atypical pneumonia. Ann Niger Med. 2017;11(1):11\u20136.","journal-title":"Ann Niger Med"},{"issue":"1","key":"953_CR62","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4104\/pcrj.2010.00014","volume":"19","author":"ML Levy","year":"2010","unstructured":"Levy ML, Le Jeune I, Woodhead MA, Macfarlaned JT, Lim WS, British Thoracic Society Community Acquired Pneumonia in Adults Guideline G. Primary care summary of the British Thoracic Society Guidelines for the management of community acquired pneumonia in adults: 2009 update. Endorsed by the Royal College of General Practitioners and the Primary Care Respiratory Society UK. Prim Care Respir J. 2010;19(1):21\u20137.","journal-title":"Prim Care Respir J"},{"key":"953_CR63","volume-title":"\u201cPneumonia\u201d, Harrison\u2019s principles of internal medicine","author":"L Mandell","year":"2008","unstructured":"Mandell L, Wunderink RG. \u201cPneumonia\u201d, Harrison\u2019s principles of internal medicine. 18th ed. New York: McGraw-Hill; 2008.","edition":"18"},{"issue":"Suppl 1","key":"953_CR64","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1093\/ofid\/ofy263","volume":"6","author":"HS Sader","year":"2019","unstructured":"Sader HS, Mendes RE, Le J, Denys G, Flamm RK, Jones RN. Antimicrobial susceptibility of Streptococcus pneumoniae from North America, Europe, Latin America, and the Asia-Pacific Region: results from 20\u00a0years of the SENTRY Antimicrobial Surveillance Program (1997\u20132016). Open Forum Infect Dis. 2019;6(Suppl 1):S14\u201323.","journal-title":"Open Forum Infect Dis"},{"issue":"8","key":"953_CR65","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1164\/rccm.201301-0079OC","volume":"188","author":"Y Shindo","year":"2013","unstructured":"Shindo Y, Ito R, Kobayashi D, Ando M, Ichikawa M, Shiraki A, et al. Risk factors for drug-resistant pathogens in community-acquired and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2013;188(8):985\u201395.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"953_CR66","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1186\/s12879-018-3565-z","volume":"18","author":"A Gramegna","year":"2018","unstructured":"Gramegna A, Sotgiu G, Di Pasquale M, Radovanovic D, Terraneo S, Reyes LF, et al. Atypical pathogens in hospitalized patients with community-acquired pneumonia: a worldwide perspective. BMC Infect Dis. 2018;18(1):677.","journal-title":"BMC Infect Dis"},{"key":"953_CR67","unstructured":"The Center for Disease Dynamics EP. ResistanceMap: resistance of Streptococcus pneumoniae to macrolides 2020. https:\/\/resistancemap.cddep.org\/AntibioticResistance.php."},{"issue":"10","key":"953_CR68","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1093\/cid\/cix549","volume":"65","author":"DM Musher","year":"2017","unstructured":"Musher DM, Abers MS, Bartlett JG. Evolving understanding of the causes of pneumonia in adults, with special attention to the role of pneumococcus. Clin Infect Dis. 2017;65(10):1736\u201344.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"953_CR69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.21037\/arh.2017.12.03","volume":"2","author":"C Cill\u00f3niz","year":"2018","unstructured":"Cill\u00f3niz C, Cardozo C, Garc\u00eda-Vidal C. Epidemiology, pathophysiology, and microbiology of community acquired pneumonia. Ann Res Hosp. 2018;2(1):1\u201311. https:\/\/doi.org\/10.21037\/arh.2017.12.03.","journal-title":"Ann Res Hosp."},{"key":"953_CR70","unstructured":"Keedy K, Nenninger A, Sheets A, et al., editors. Antibiotic susceptibility of Streptococcus pneumoniae in the US in 2014. Poster Presentation. ID Week. New Orleans: Infectious Diseases Society of America; 2016."},{"issue":"1","key":"953_CR71","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1086\/380126","volume":"38","author":"E Nuermberger","year":"2004","unstructured":"Nuermberger E, Bishai WR. The clinical significance of macrolide-resistant Streptococcus pneumoniae: it\u2019s all relative. Clin Infect Dis. 2004;38(1):99\u2013103.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"953_CR72","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ijantimicag.2004.03.008","volume":"24","author":"M Rzeszutek","year":"2004","unstructured":"Rzeszutek M, Wierzbowski A, Hoban DJ, Conly J, Bishai W, Zhanel GG. A review of clinical failures associated with macrolide-resistant Streptococcus pneumoniae. Int J Antimicrob Agents. 2004;24(2):95\u2013104.","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"953_CR73","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1128\/CMR.00058-15","volume":"29","author":"L Kim","year":"2016","unstructured":"Kim L, McGee L, Tomczyk S, Beall B. Biological and epidemiological features of antibiotic-resistant Streptococcus pneumoniae in pre- and post-conjugate vaccine eras: a United States perspective. Clin Microbiol Rev. 2016;29(3):525\u201352.","journal-title":"Clin Microbiol Rev"},{"issue":"6","key":"953_CR74","doi-asserted-by":"crossref","first-page":"905","DOI":"10.3201\/eid1506.080684","volume":"15","author":"AG de la Campa","year":"2009","unstructured":"de la Campa AG, Ardanuy C, Balsalobre L, Perez-Trallero E, Marimon JM, Fenoll A, et al. Changes in fluoroquinolone-resistant Streptococcus pneumoniae after 7-valent conjugate vaccination, Spain. Emerg Infect Dis. 2009;15(6):905\u201311.","journal-title":"Emerg Infect Dis"},{"issue":"1","key":"953_CR75","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1164\/ajrccm.162.1.9907023","volume":"162","author":"F Arancibia","year":"2000","unstructured":"Arancibia F, Ewig S, Martinez JA, Ruiz M, Bauer T, Marcos MA, et al. Antimicrobial treatment failures in patients with community-acquired pneumonia: causes and prognostic implications. Am J Respir Crit Care Med. 2000;162(1):154\u201360.","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"953_CR76","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1128\/AAC.01169-07","volume":"52","author":"CG Giske","year":"2008","unstructured":"Giske CG, Monnet DL, Cars O, Carmeli Y, ReAct-Action on Antibiotic R. Clinical and economic impact of common multidrug-resistant gram-negative bacilli. Antimicrob Agents Chemother. 2008;52(3):813\u201321.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"953_CR77","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1586\/eri.13.12","volume":"11","author":"JN Pendleton","year":"2013","unstructured":"Pendleton JN, Gorman SP, Gilmore BF. Clinical relevance of the ESKAPE pathogens. Expert Rev Anti Infect Ther. 2013;11(3):297\u2013308.","journal-title":"Expert Rev Anti Infect Ther"},{"key":"953_CR78","unstructured":"Gupta V, Yu K, Jokinen-Gordon H, Gelone SP. A multi-centre evaluation of the US prevalence and regional variation in macrolide-resistant Streptococcus pneumoniae from blood or respiratory cultures among adult patients. Abstract #5523. Presented at 30th European congress on clinical microbiology and infectious diseases (ECCMID), Paris, France, April 18\u201321, 2020."},{"issue":"2","key":"953_CR79","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1086\/313959","volume":"31","author":"LA Mandell","year":"2000","unstructured":"Mandell LA, Marrie TJ, Grossman RF, Chow AW, Hyland RH. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. The Canadian Community-Acquired Pneumonia Working Group. Clin Infect Dis. 2000;31(2):383\u2013421.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"953_CR80","first-page":"272","volume":"41","author":"I Alfageme","year":"2005","unstructured":"Alfageme I, Aspa J, Bello S, Blanquer J, Blanquer R, Borderias L, et al. Guidelines for the diagnosis and management of community-acquired pneumonia. Spanish Society of Pulmonology and Thoracic Surgery (SEPAR). Arch Bronconeumol. 2005;41(5):272\u201389.","journal-title":"Arch Bronconeumol"},{"issue":"2","key":"953_CR81","first-page":"90","volume":"70","author":"WJ Wiersinga","year":"2012","unstructured":"Wiersinga WJ, Bonten MJ, Boersma WG, Jonkers RE, Aleva RM, Kullberg BJ, et al. SWAB\/NVALT (Dutch Working Party on Antibiotic Policy and Dutch Association of Chest Physicians) guidelines on the management of community-acquired pneumonia in adults. Neth J Med. 2012;70(2):90\u2013101.","journal-title":"Neth J Med"},{"issue":"4","key":"953_CR82","first-page":"241","volume":"39","author":"JM Qu","year":"2016","unstructured":"Qu JM, Cao B. Guidelines for the diagnosis and treatment of adult community acquired pneumonia in China (2016 Edition). Zhonghua Jie He He Hu Xi Za Zhi. 2016;39(4):241\u20132.","journal-title":"Zhonghua Jie He He Hu Xi Za Zhi"},{"issue":"7","key":"953_CR83","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2169\/internalmedicine.45.1691","volume":"45","author":"N Miyashita","year":"2006","unstructured":"Miyashita N, Matsushima T, Oka M, Japanese Respiratory S. The JRS guidelines for the management of community-acquired pneumonia in adults: an update and new recommendations. Intern Med. 2006;45(7):419\u201328.","journal-title":"Intern Med"},{"key":"953_CR84","doi-asserted-by":"crossref","first-page":"j2471","DOI":"10.1136\/bmj.j2471","volume":"358","author":"RG Wunderink","year":"2017","unstructured":"Wunderink RG, Waterer G. Advances in the causes and management of community acquired pneumonia in adults. BMJ. 2017;358:j2471.","journal-title":"BMJ"},{"key":"953_CR85","doi-asserted-by":"crossref","first-page":"g6722","DOI":"10.1136\/bmj.g6722","volume":"349","author":"S Eccles","year":"2014","unstructured":"Eccles S, Pincus C, Higgins B, Woodhead M, Guideline Development G. Diagnosis and management of community and hospital acquired pneumonia in adults: summary of NICE guidance. BMJ. 2014;349:g6722.","journal-title":"BMJ"},{"key":"953_CR86","doi-asserted-by":"crossref","first-page":"c2016","DOI":"10.1136\/bmj.c2016","volume":"340","author":"R Lilford","year":"2010","unstructured":"Lilford R, Pronovost P. Using hospital mortality rates to judge hospital performance: a bad idea that just won\u2019t go away. BMJ. 2010;340:c2016.","journal-title":"BMJ"},{"issue":"21","key":"953_CR87","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1001\/jama.2013.5009","volume":"309","author":"JM Kupfer","year":"2013","unstructured":"Kupfer JM. The morality of using mortality as a financial incentive: unintended consequences and implications for acute hospital care. JAMA. 2013;309(21):2213\u20134.","journal-title":"JAMA"},{"issue":"6","key":"953_CR88","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1001\/jama.2016.0115","volume":"315","author":"JS Lee","year":"2016","unstructured":"Lee JS, Giesler DL, Gellad WF, Fine MJ. Antibiotic therapy for adults hospitalized with community-acquired pneumonia: a systematic review. JAMA. 2016;315(6):593\u2013602.","journal-title":"JAMA"},{"issue":"3","key":"953_CR89","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.ijantimicag.2015.04.010","volume":"46","author":"A Raz-Pasteur","year":"2015","unstructured":"Raz-Pasteur A, Shasha D, Paul M. Fluoroquinolones or macrolides alone versus combined with beta-lactams for adults with community-acquired pneumonia: systematic review and meta-analysis. Int J Antimicrob Agents. 2015;46(3):242\u20138.","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"953_CR90","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/QCO.0000000000000526","volume":"32","author":"MH Kollef","year":"2019","unstructured":"Kollef MH, Betthauser KD. New antibiotics for community-acquired pneumonia. Curr Opin Infect Dis. 2019;32(2):169\u201375.","journal-title":"Curr Opin Infect Dis"},{"key":"953_CR91","unstructured":"NUZYRA\u2122 (omadacycline)) product package insert. Boston, MA.: Paratek Pharmaceuticals Inc.; 2018."},{"issue":"6","key":"953_CR92","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1056\/NEJMoa1800201","volume":"380","author":"R Stets","year":"2019","unstructured":"Stets R, Popescu M, Gonong JR, Mitha I, Nseir W, Madej A, et al. Omadacycline for community-acquired bacterial pneumonia. N Engl J Med. 2019;380(6):517\u201327.","journal-title":"N Engl J Med"},{"issue":"Supplement_1","key":"953_CR93","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1093\/cid\/ciz394","volume":"69","author":"JC Gallagher","year":"2019","unstructured":"Gallagher JC. Omadacycline: a modernized tetracycline. Clin Infect Dis. 2019;69(Supplement_1):S1\u20135.","journal-title":"Clin Infect Dis"},{"issue":"11","key":"953_CR94","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1093\/cid\/ciz710","volume":"70","author":"TM File","year":"2020","unstructured":"File TM, Goldberg L, Das A, Sweeney C, Saviski J, Gelone SP, et al. Efficacy and safety of intravenous-to-oral lefamulin, a pleuromutilin antibiotic, for the treatment of community-acquired bacterial pneumonia: the phase III lefamulin evaluation against pneumonia (LEAP 1) trial. Clin Infect Dis. 2020;70(11):2459. https:\/\/doi.org\/10.1093\/cid\/ciz710.","journal-title":"Clin Infect Dis."},{"key":"953_CR95","unstructured":"U.S. Food and Drug Administration.\u00a0FDA approves new antibiotic to treat community-acquired bacterial pneumonia. [press release]. August 19, 2019. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-antibiotic-treat-community-acquired-bacterial-pneumonia. Accessed 10 Oct 2019."},{"key":"953_CR96","volume-title":"Nabriva Therapeutics receives U.S. FDA approval of XenletaTM (lefamulin) to treat community-acquired bacterial pneumonia (CABP) [press release]","author":"Nabriva Therapeutics US, Inc","year":"2019","unstructured":"Nabriva Therapeutics US, Inc. Nabriva Therapeutics receives U.S. FDA approval of XenletaTM (lefamulin) to treat community-acquired bacterial pneumonia (CABP) [press release]. Dublin: Nabriva Therapeutics US, Inc; 2019."},{"issue":"8","key":"953_CR97","doi-asserted-by":"crossref","first-page":"270","DOI":"10.3390\/microorganisms7080270","volume":"7","author":"D Koulenti","year":"2019","unstructured":"Koulenti D, Xu E, Mok IYS, Song A, Karageorgopoulos DE, Armaganidis A, et al. Novel antibiotics for multidrug-resistant gram-positive microorganisms. Microorganisms. 2019;7(8):270.","journal-title":"Microorganisms."},{"issue":"12","key":"953_CR98","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1086\/657313","volume":"51","author":"TM File Jr","year":"2010","unstructured":"File TM Jr, Low DE, Eckburg PB, Talbot GH, Friedland HD, Lee J, et al. Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia. Clin Infect Dis. 2010;51(12):1395\u2013405.","journal-title":"Clin Infect Dis"},{"key":"953_CR99","unstructured":"Sader HS, Flamm R, Streit JM, Mendes RE. Frequency of occurrence and antimicrobial susceptibility of bacteria isolated from patients hospitalised with community-acquired bacterial pneumonia: evaluation of ceftaroline potency and antimicrobial spectrum. #P1817. Poster session presented at 28th European congress on clinical microbiology and infectious diseases (ECCMID),\u00a0Madrid, Spain, 21\u201324 April 2018."},{"issue":"4","key":"953_CR100","doi-asserted-by":"crossref","first-page":"e02609-16","DOI":"10.1128\/AAC.02609-16","volume":"61","author":"MA Pfaller","year":"2017","unstructured":"Pfaller MA, Sader HS, Rhomberg PR, Flamm RK. In vitro activity of delafloxacin against contemporary bacterial pathogens from the United States and Europe, 2014. Antimicrob Agents Chemother. 2017;61(4):e02609-16.","journal-title":"Antimicrob Agents Chemother."},{"issue":"Suppl 1","key":"953_CR101","doi-asserted-by":"crossref","first-page":"S373","DOI":"10.1093\/ofid\/ofx163.918","volume":"4","author":"RK Flamm","year":"2017","unstructured":"Flamm RK, Shortridge D, Huband MD, McCurdy S, Pfaller MA. Activity of delafloxacin when tested against bacterial surveillance isolates collected in the US and Europe during 2014\u20132016 as part of a global surveillance program. Open Forum Infect Dis. 2017;4(Suppl 1):S373\u20134.","journal-title":"Open Forum Infect Dis"},{"issue":"S1","key":"953_CR102","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1093\/ofid\/ofw172.1520","volume":"3","author":"S Bhavnani","year":"2016","unstructured":"Bhavnani S, Zhang L, Rubino C, Bader J, Lepak A, Andes D, et al. Pharmacokinetic\u2013pharmacodynamic (PK\u2013PD) target attainment analyses for delafloxacin to provide dose selection support for the treatment of patients with community-acquired bacterial pneumonia (CABP). Open Forum Infect Dis. 2016;3(S1):1972.","journal-title":"Open Forum Infect Dis."},{"issue":"1","key":"953_CR103","doi-asserted-by":"crossref","first-page":"ofz514","DOI":"10.1093\/ofid\/ofz514","volume":"7","author":"JP Horcajada","year":"2019","unstructured":"Horcajada JP, Salata RA, \u00c1lvarez-Sala R, Nitu FM, Lawrence L, Quintas M, et al. A phase 3 study to compare delafloxacin with moxifloxacin for the treatment of adults with community-acquired bacterial pneumonia (DEFINE-CABP). Open Forum Infect Dis. 2019;7(1):ofz514.","journal-title":"Open Forum Infect Dis."},{"issue":"3","key":"953_CR104","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1093\/jac\/dkv411","volume":"71","author":"J Kingsley","year":"2016","unstructured":"Kingsley J, Mehra P, Lawrence LE, Henry E, Duffy E, Cammarata SK, et al. A randomized, double-blind, phase 2 study to evaluate subjective and objective outcomes in patients with acute bacterial skin and skin structure infections treated with delafloxacin, linezolid or vancomycin. J Antimicrob Chemother. 2016;71(3):821\u20139.","journal-title":"J Antimicrob Chemother"},{"key":"953_CR105","unstructured":"Longcor J, Hopkins S, Wikler M, Lawrence L. A phase 2 safety and efficacy study of oral delafloxacin (DLX) in subjects with acute bacterial exacerbation of chronic bronchitis (ABECB). Abstract 1071. Poster abstract session: lower respiratory tract infection. ID Week, San Diego, CA, October 17\u201321, 2012. https:\/\/idsa.confex.com\/idsa\/2012\/webprogram\/Paper37662.html."},{"key":"953_CR106","doi-asserted-by":"crossref","unstructured":"McCurdy S, Keedy K, Lawrence L, et al., editors. Analysis of the microbiological data from the delafloxacin phase 3 community acquired bacterial pneumonia (CABP). Poster 2230. ID Week; 2\u20136 October 2019. Washington, D.C.: Infectious Disease Society of America; 2019.","DOI":"10.1093\/ofid\/ofz360.1908"},{"key":"953_CR107","doi-asserted-by":"crossref","unstructured":"Kaidashev I, Nitu F, Popescu M, editors. Treatment of community acquired bacterial pneumonia (CABP) in patients with diabetes: outcomes from a global phase 3 study of delafloxacin. Poster 2228. ID Week; 2\u20136 October 2019. Washington, D.C.: Infectious Diseases Society of America; 2019.","DOI":"10.1093\/ofid\/ofz360.1906"},{"key":"953_CR108","doi-asserted-by":"crossref","unstructured":"Madej A, Pullman J, Popescu M, editors. Outcomes by age and gender from a global phase 3 study of delafloxacin (DLX) in community acquired bacterial pneumonia (CABP). Poster 2234. ID Week; 2\u20136 October 2019; Washington, D.C.: Infectious Diseases Society of America; 2019.","DOI":"10.1093\/ofid\/ofz360.1912"},{"issue":"1","key":"953_CR109","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/phar.2050","volume":"38","author":"JC Cho","year":"2018","unstructured":"Cho JC, Crotty MP, White BP, Worley MV. What is old is new again: delafloxacin, a modern fluoroquinolone. Pharmacotherapy. 2018;38(1):108\u201321.","journal-title":"Pharmacotherapy"},{"key":"953_CR110","unstructured":"Inc. BHP. CIPRO\u00ae (ciprofloxacin hydrochloride) Package Insert Whippany, NJ, USA. 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/019537s086lbl.pdf."},{"key":"953_CR111","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.2217\/fmb-2018-0067","volume":"13","author":"M Bassetti","year":"2018","unstructured":"Bassetti M, Righi E, Pecori D, Tillotson G. Delafloxacin: an improved fluoroquinolone developed through advanced molecular engineering. Future Microbiol. 2018;13:1081\u201394.","journal-title":"Future Microbiol"},{"issue":"2","key":"953_CR112","first-page":"132","volume":"6","author":"CB Pasquale","year":"2019","unstructured":"Pasquale CB, Vietri J, Choate R, McDaniel A, Sato R, Ford KD, et al. Patient-reported consequences of community-acquired pneumonia in patients with chronic obstructive pulmonary disease. Chronic Obstr Pulm Dis. 2019;6(2):132\u201344.","journal-title":"Chronic Obstr Pulm Dis"},{"issue":"10","key":"953_CR113","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1136\/thoraxjnl-2015-206780","volume":"70","author":"A Torres","year":"2015","unstructured":"Torres A, Blasi F, Dartois N, Akova M. Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and\/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease. Thorax. 2015;70(10):984\u20139.","journal-title":"Thorax"}],"updated-by":[{"DOI":"10.1007\/s40261-020-00998-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,1,28]],"date-time":"2021-01-28T00:00:00Z","timestamp":1611792000000}}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-020-00953-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-020-00953-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-020-00953-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,4]],"date-time":"2021-09-04T23:15:07Z","timestamp":1630797307000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-020-00953-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,5]]},"references-count":113,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["953"],"URL":"https:\/\/doi.org\/10.1007\/s40261-020-00953-z","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40261-020-00998-0","asserted-by":"object"}]},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,5]]},"assertion":[{"value":"5 September 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2021","order":2,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40261-020-00998-0","URL":"https:\/\/doi.org\/10.1007\/s40261-020-00998-0","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"CS has served as a speaker for Allergan, Merck, Nabriva, and Paratek Pharmaceuticals, and has received consulting fees for working on clinical trials for Allergan, Shionogi, and Merck. Additionally, CS has received research grants from CMS, NIH and CDC, not for this manuscript but for work with Allergan, Shionogi, and Merck. RS, JM, and NT have no conflicts of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"No funding was provided for the preparation of this review.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}}]}}